Development of novel targeted therapies in the treatment of malignant glioma

@article{Rich2004DevelopmentON,
  title={Development of novel targeted therapies in the treatment of malignant glioma},
  author={Jeremy Rich and Darell D Bigner},
  journal={Nature Reviews Drug Discovery},
  year={2004},
  volume={3},
  pages={430-446}
}
Malignant gliomas are highly lethal tumours despite maximal therapy. Traditional treatments for these cancers — which rely on nonspecific, cytotoxic approaches that generally act through damaging DNA — have a marginal impact on patient survival. However, advances in the understanding of the molecular biology underlying glioma pathogenesis have revealed abnormalities in a set of common cellular pathways and functions among the majority of these tumours that are now being targeted by novel agents… CONTINUE READING
104 Citations
232 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 104 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 232 references

Phase II trial of gefitinib in recurrent glioblastoma

  • Rich, N J.
  • J. Clin. Oncol
  • 2004

a Phase III trial — INTACT 1

  • Giaccone, G. et al. Gefitinib in combination with gemcitabine, cisplatin in advanced non-small-cell lung cancer
  • J. Clin. Oncol. 22, 777–784
  • 2004

a Phase III trial — INTACT 2

  • Herbst, R. S. et al. Gefitinib in combination with paclitaxel, carboplatin in advanced non-small-cell lung cancer
  • J. Clin. Oncol. 22, 785–794
  • 2004

A TGF - β 2 specific antisense oligonucleotide ( AP 12009 ) as continuous intratumoral treatment of recurrent high - grade glioma patients : A clinical phase I / II extension study

  • J. N. Rich, M. Zhang, M. B. Datto, D. D. Bigner, X. F. Wang
  • Proc . Am . Soc . Clin . Oncol .
  • 2003

A clinical phase I/II extension study

  • Stauder, G. M. et al. A TGF-β2 specific antisense oligonucleot patients
  • Proc. Am. Soc. Clin. Oncol. 22, 109
  • 2003

Similar Papers

Loading similar papers…